These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37023729)

  • 1. Real-World Experience of PD-1 Inhibitors for Relapsed and Refractory Hodgkin Lymphoma: A Multicenter Retrospective Analysis of Patients in China.
    Yu W; Geng M; Hao J; Yan Z; Mi JQ
    Acta Haematol; 2023; 146(4):307-315. PubMed ID: 37023729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
    Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
    Song Y; Gao Q; Zhang H; Fan L; Zhou J; Zou D; Li W; Yang H; Liu T; Wang Q; Lv F; Guo H; Yang L; Elstrom R; Huang J; Novotny W; Wei V; Zhu J
    Leukemia; 2020 Feb; 34(2):533-542. PubMed ID: 31520078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma].
    Shan DD; Liu HM; Liu W; Huang WY; Lyu R; Deng SH; Yi SH; An G; Xu Y; Sui WW; Wang TY; Fu MW; Zhao YZ; Qiu LG; Zou DH
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):555-560. PubMed ID: 37749034
    [No Abstract]   [Full Text] [Related]  

  • 6. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.
    Maruyama D; Hatake K; Kinoshita T; Fukuhara N; Choi I; Taniwaki M; Ando K; Terui Y; Higuchi Y; Onishi Y; Abe Y; Kobayashi T; Shirasugi Y; Tobinai K
    Cancer Sci; 2017 May; 108(5):1007-1012. PubMed ID: 28267244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma.
    Song Y; Wu J; Chen X; Lin T; Cao J; Liu Y; Zhao Y; Jin J; Huang H; Hu J; Luo J; Zhang L; Xue H; Zhang Q; Wang W; Chen C; Feng J; Zhu J
    Clin Cancer Res; 2019 Dec; 25(24):7363-7369. PubMed ID: 31420358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China.
    Yu W; Huang L; Mei H; Li Y; Niu T; Zou D; Liu Y; Zhang H; Liu P; Wu J; Wang Z; Li H; Cai Q; Mi JQ
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38802271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.
    Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
    Cancer Med; 2020 Nov; 9(21):7830-7836. PubMed ID: 32881376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies.
    Sun C; Chen H; Wang Y; Zheng C
    Hematology; 2023 Dec; 28(1):2181749. PubMed ID: 36892260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
    Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy.
    Wang C; Liu Y; Dong L; Li X; Yang Q; Brock MV; Mei Q; Liu J; Chen M; Shi F; Liu M; Nie J; Han W
    Clin Cancer Res; 2021 May; 27(10):2782-2791. PubMed ID: 33674274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study.
    Yan Z; Ma J; Yao S; Yao Z; Wang H; Chu J; Zhao S; Liu Y
    Front Immunol; 2021; 12():727464. PubMed ID: 34899689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
    Hanel W; Shindiapina P; Bond DA; Sawalha Y; Epperla N; Voorhees T; Welkie RL; Huang Y; Behbehani GK; Zhang X; McLaughlin E; Chan WK; Brammer JE; Jaglowski S; Reneau JC; Christian BA; William BM; Cohen JB; Baiocchi RA; Maddocks K; Blum KA; Alinari L
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
    De Filippi R; Morabito F; Santoro A; Tripepi G; D'Alò F; Rigacci L; Ricci F; Morelli E; Zinzani PL; Pinto A
    J Transl Med; 2021 Dec; 19(1):489. PubMed ID: 34852840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma.
    Gaudio F; Loseto G; Bozzoli V; Scalzulli PR; Mazzone AM; Tonialini L; Fesce V; Quintana G; De Santis G; Masciopinto P; Arcuti E; Clemente F; Scardino S; Tarantini G; Pastore D; Melillo L; Pavone V; Maggi A; Carella AM; Di Renzo N; Guarini A; Musto P
    Ann Hematol; 2023 Feb; 102(2):385-392. PubMed ID: 36645458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
    Chan TSY; Hwang YY; Khong PL; Leung AYH; Chim CS; Tse EWC; Kwong YL
    Hematol Oncol; 2020 Dec; 38(5):726-736. PubMed ID: 32786092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.
    Armand P; Lesokhin A; Borrello I; Timmerman J; Gutierrez M; Zhu L; Popa McKiver M; Ansell SM
    Leukemia; 2021 Mar; 35(3):777-786. PubMed ID: 32601377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
    Chen R; Zinzani PL; Lee HJ; Armand P; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Lin J; Kim E; Nahar A; Balakumaran A; Moskowitz CH
    Blood; 2019 Oct; 134(14):1144-1153. PubMed ID: 31409671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.